Erschienen in:
01.04.2005 | Adis Drug Profile
Intranasal Sumatriptan
In Adolescents with Migraine
verfasst von:
Monique P. Curran, Hannah C. Evans, Antona J. Wagstaff
Erschienen in:
CNS Drugs
|
Ausgabe 4/2005
Einloggen, um Zugang zu erhalten
Abstract
▴ Sumatriptan, a serotonin 5-HT1B/1D agonist, constricts cranial blood vessels and inhibits neuroin-flammatory processes.
▴ A single dose of sumatriptan 10mg (approved European dosage) was significantly more effective than placebo in achieving headache relief at 1 hour post-dose in a well designed study. Headache relief occurred in significantly more adolescents administered a single dose of intranasal sumatriptan 20mg (at 1 and 2 hours) and 5mg (at 2 hours) than placebo (pooled data from two studies).
▴ Sustained headache relief (1–24 and 2–24 hours) occurred in significantly more recipients of a single dose of intranasal sumatriptan 20mg and 5mg than placebo (pooled data from two studies).
▴ Intranasal sumatriptan was generally well tolerated in adolescent migraineurs (in single-episode studies or long term in multiple-episode studies). Taste disturbance occurred more often with intranasal sumatriptan than with placebo.